TS
RPRX icon

Thomas Steyer’s Royalty Pharma RPRX Stock Holding History

Thomas Steyer’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-493,000
Closed -$23.6M – 166
2026
Q1 		$23.6M Buy
+493,000
New +$21.6M 0.12% 60
2020
Q3 		– Sell
-275,000
Closed -$13.4M – 133
2020
Q2 		$13.4M Buy
+275,000
New +$13.6M 0.11% 97

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thomas Steyer's RPRX Position: Q2 2026 in Review

Thomas Steyer sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 493,000 shares — an estimated $23.6M sold.

Thomas Steyer first reported a position in RPRX in Q2 2020 and held it in 2 quarters. The position peaked at $23.6M in Q1 2026. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Thomas Steyer reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 493,000 Royalty Pharma shares in Q2 2026, an estimated $23.6M.
  • Thomas Steyer first reported a position in Royalty Pharma in Q2 2020 and held it in 2 quarters.
  • Thomas Steyer's Royalty Pharma position peaked at $23.6M in Q1 2026.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.